胃癌铂类化疗预后与XRCC1多态性关系  

Single nucleotide polymorphisms in XRCC1 and outcome in gastric cancer patients receiving oxaliplatin based chemotherapy

作　　者：魏嘉[1] 张微[1] 邹征云[1] 钱晓萍[1] 禹立霞[1] 刘宝瑞[1] 

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心,南京210008

出　　处：《中国公共卫生》2007年第7期839-840,共2页Chinese Journal of Public Health

基　　金：南京市医学重点科技发展项目(ZKX05015);江苏省卫生厅科研项目(H200640)

摘　　要：目的探讨外周血X线交错互补修复基因1(XRCC1)单核苷酸多态性与接受铂类药物化疗胃癌患者生存时间关系。方法经病理确诊胃癌患者62例,治疗前提取其外周血DNA,采用TaqMan探针Real-time PCR方法对XRCC1第399位密码子进行多态性分析,并比较其基因型与接受铂类化疗患者生存时间关系。结果62例胃癌患者平均总生存时间为461 d,携带XRCC1 Arg/Arg或Arg/Gln基因型胃癌患者的平均总生存时间为490 d,而携带Gln/Gln基因型患者的平均总生存时间仅为295 d,差异有统计学意义(P=0.022)。结论XRCC1基因多态性与接受铂类化疗的胃癌患者的总生存时间明显相关。Objective To investigate whether the single nucleotide polymorphism （SNP） in DNA repair gene XRCC1 （X-ray repair cross-complementing 1 ） were associated with the survival of 5-FU/oxaliplatin combination chemotherapy in gastric cancer, Methods Overau survival time of 62 gastric cancer patients receiving platinum-based chemotherapy were investigated. XRCC1 genotypes were assessed using 5＇ nuclease allelic discrimination assay （TaqMan） using real-time PCR. Resuits The median survival time of all 62 gastric patients was 461 days. The median survival time of patients with Arg/Arg or Arg/Gln genotypes was 490 days compared with 295 days of others （ P = 0. 022）. Conclusion XRCC1 399 SNP was predictive marker of survival for gastric cancer patients receiving platinum-based chemotherapy.

关 键 词：DNA修复基因 XRCC1 单核苷酸多态性(SNP) 胃癌 化疗 

分 类 号：R73-361[医药卫生—肿瘤]